The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Bermuda, funny enough had never seen the article from 2010, although many references were made about Amy Dickinson a couple of years later. Just about half of those were in the Daily Mail too. Funny to think that was 9 years ago now, well funny if you have a good sense of humour!!! I seem to remember an FT article had a very positive effect on the SP at the time, but was never followed up. You have a very good filing system there Berm.
Moljen, something like that, what I do know we were so poor also the goal made little difference to me. Well done though a very good 3 points for your guys.
Interesting list - looked at 2 at random, one from 2011 and one from Feb 18. The first is yikes that long and the second I looked at the share price around then, went from 10 to 17.5p, make of those what you will.
C7 - Saturday was blatant highway robbery aided and insisted by Hazard no longer being with you. Lack of guile to breakdown admittedly a very un-entertaining but superbly organised defence, we should be playing in Serie A :-)
To reinforce Ray's point, Scancell have had their fair share of media coverage - a few below and am sure there were many more. How many of them can you actually remember and did they have any impact?
https://www.dailymail.co.uk/health/article-1278836/Holy-Grail-cancer-vaccine-blasts-tumours-weeks-hailed-huge-leap-fighting-disease.html
https://www.dailymail.co.uk/health/article-5376825/Experts-develop-revolutionise-skin-cancer-jab.html
https://www.dailymail.co.uk/health/article-2031506/Electric-jab-arm-fights-skin-cancer.html
https://www.telegraph.co.uk/business/2017/06/26/pioneering-british-firm-wins-patent-cancer-vaccines-technology/
https://www.thetimes.co.uk/article/cancer-drugs-give-pharma-shot-in-arm-sqgcgt2sp9g
https://www.independent.co.uk/news/business/news/uk-cancer-vaccine-technology-patent-granted-scancell-immunobody-scib1-a7808986.html
https://www.ft.com/content/d0a2225c-86e2-11e9-97ea-05ac2431f453
Still got that feeling there is another item of news to come with the Interims, perhaps before the end of this month. Any updates surely must include the SCIB1 trial and another good news RNS will take negative focus away from it being delayed. I still do think the chances of hearing we can re submit the IND to the FDA could be very real, there has certainly been time for Ichor and the FDA to sort out the issues under question.
C7
I think the interest has always been there. It's just not been visible until Scancell opened their doors to pre-clinical collaborations.
Just saying it straight Ray, do you believe hospitals with research udgets to fill put out such positive articles to help direct funding into their trials?? Something i have long thought but never wanted to say.
But I do think this third collaboration will create a lot of interest in the Industry and for a second time in a month we hit over 40 trades, today 41, which is very rare for us. Be interesting to see volume tomorrow, last time the Holdings RNS built on a 13% rise for the second collaboration, we do have a buyer busy collecting more, nice 250k and 1m buys today and even taking off the 390k trades we had 2 x 150k buys Friday apart from a few hefty buys all last week.
I'm not sure I agree.
Sure, Scancell could have an article about them on the BBC website and it would attract some interest.
But how long would that interest last and would the Beeb be likely to follow up on the article before the next big story breaks.
So you would probably end up with a temporary effect. Much like a lot of Scancell's news items. In fact, even with today's news item we do not know how long the effect will last.
IMO, what is of more importance is that scientists in other companies and countries are recognising the worth of Scancell's products and persuading their management that a closer look is required.
The result is 4 pre-clinical collaborations.
How many more would there have been if Scancell were looking for pre-clinical deals on their 2 main platforms.
So, as investors, you look for accumulated evidence that Scancell have indeed something worth shouting about.
For me, that accumulated evidence is in the 4 collaborations, the CAB, the GC team members, the SCIB1 peer reviews, Keith Flaherty's support for SCIB1, CRUK funding and running the SCIB2 trial, Lindy winning the Waldenström prize, Diggles following Peter James's advice.
All of the above are endorsements from scientists.
So, if the Daily Mail or the BBC published an article about Scancell tomorrow, that wouldn't make my list. It might make nice reading though.
The sustained price rises will come with trials starting (with patients), data and deals. We all hope this eventually starts to happen this year.
Was thinking the same Moljen, didn"t like to say it though.
Think I owe you a well done for Saturday??
Shame we rarely see articles on our work appearing on such a high profile site, likewise also agree too early but in the limited world of funds to trial the more options there are the more you need to be shouting "we're here" otherwise you risk of being just another has been irrespective
That is the problem, how many such articles have we read like that in the last 8 years?? Too many.
Hi- that’s journalism and 20+ years away even if it did work and was translatable from the lab to a fully tested product.
early days
https://elifesciences.org/articles/24476
this group in Switzerland have also seen this MR1
how effective ? no idea to early to say, as we all know .. talk in the lab to clinical trial is a long procedure
Perhaps one for the more scientific amongst you to discuss - threat?
https://www.bbc.co.uk/news/health-51182451